Ipamorelin — Research Overview
Chemical Name: Ipamorelin Also Known As: NNC-26-0161, ipamorelin acetate (salt form) Amino Acid Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH2 Structure: Synthetic pentapeptide (5 amino acids) GHS-R1a agonist. Notably contains alpha-aminoisobutyric acid (Aib) at position 1 — a non-natural amino acid that does not occur in the GHRP-6 or GHRP-2 scaffolds — and was identified through a chemistry program that eliminated the central Ala-Trp dipeptide of GHRP-1. Molecular Weight: Approximately 711.9 daltons Developer: Originally developed by Novo Nordisk in Denmark in the late 1990s Historical Position in the GHRP Class: Third-generation GH secretagogue. GHRP-6 (1984) was the foundational first-generation compound. GHRP-2 and hexarelin followed as more potent second-generation analogs. Ipamorelin emerged from a Novo Nordisk chemistry program as the first compound in the class to achieve GH release selectivity equivalent to GHRH — making it the first GHRP-receptor agonist that does not significantly elevate ACTH, cortisol, or prolactin. Regulatory Status: Not approved by the FDA for any therapeutic indication. Has been evaluated in Phase 2 randomized controlled trials (postoperative ileus). The FDA has examined ipamorelin-related bulk drug substances in the context of pharmaceutical compounding. WADA Status: Prohibited under S2 (peptide hormones, growth factors, related substances, and mimetics) Category: Selective synthetic GHS-R1a agonist / selective growth hormone secretagogue / third-generation GHRP / ghrelin mimetic / gastrointestinal promotility research compound
Research Use Only — Disclaimer
The scientific literature on this page is provided strictly for educational and informational purposes. All Rogue Compounds products are intended for in-vitro laboratory research use only and are not approved by the FDA for human or animal consumption. The studies referenced below are independent third-party peer-reviewed publications. Rogue Compounds makes no claims that any product diagnoses, treats, cures, or prevents any disease or condition. Researchers are responsible for compliance with all applicable local, state, and federal regulations.
What Is Ipamorelin?
Ipamorelin is a synthetic pentapeptide growth hormone secretagogue developed by Novo Nordisk in Denmark and first characterized in 1998. It represents the third generation of the GHRP family — the class of synthetic ghrelin mimetics originally pioneered by Cyril Bowers with the characterization of GHRP-6 in 1984. Ipamorelin was discovered through a systematic chemistry program aimed at developing GHS-R1a agonists with improved selectivity, identifying the compound within a series that eliminated the central Ala-Trp dipeptide present in GHRP-1 and its analogs.
The defining characteristic that distinguishes ipamorelin from every earlier member of the GHRP class is its hormonal selectivity. When the foundational 1998 paper was published in the European Journal of Endocrinology, its key finding was described by the authors as “very surprising” — ipamorelin produced robust GH release without elevating ACTH or cortisol at doses more than 200-fold above the effective dose for GH release. This was unprecedented in the GHRP class: GHRP-6 and GHRP-2 both produced ACTH and cortisol responses comparable in magnitude to human corticotropin-releasing hormone at GH-releasing doses. Ipamorelin did not. Furthermore, ipamorelin produced minimal appetite stimulation compared to GHRP-6, which elicits the strongest orexigenic response in the class. And unlike hexarelin, ipamorelin does not produce pronounced receptor desensitization (tachyphylaxis) with repeated dosing.
This selectivity profile — potent GH release, without HPA axis activation, without significant prolactin elevation, without pronounced appetite stimulation, without rapid tachyphylaxis — made ipamorelin the preferred GHRP for research applications requiring clean GH axis stimulation and for clinical development where the cortisol elevation of earlier GHRPs would have been a safety or confounding concern.
Beyond GH secretagogy, ipamorelin has been studied as a gastrointestinal promotility agent through GHS-R1a receptors expressed in the gut, advancing to at least one Phase 2 randomized controlled clinical trial in postoperative ileus — making it one of the most clinically evaluated GHRP compounds alongside pralmorelin (GHRP-2).
The Selectivity Discovery in Context
To understand why ipamorelin’s selectivity was scientifically significant, the background of GHRP class pharmacology is essential. All earlier synthetic GHS-R1a agonists — GHRP-6, GHRP-2, hexarelin, GHRP-1 — produced GH release but also activated secondary hormone pathways including ACTH/cortisol and prolactin. This multi-hormone effect was generally attributed to GHS-R1a’s widespread expression beyond pituitary somatotrophs, including in hypothalamic neurons that regulate HPA axis function and in other pituitary cell types.
For GH research applications, the co-elevation of cortisol was a confounding variable — cortisol itself has GH-antagonizing and catabolic properties, making the net physiological response to earlier GHRPs a mixture of anabolic and catabolic signals. For long-term clinical use, the HPA axis activation was a safety concern for protocols involving repeated dosing.
Ipamorelin’s discovery that GHS-R1a agonism and HPA axis activation could be pharmacologically separated — by appropriate structural modification of the GHRP scaffold — fundamentally changed the research landscape for selective GH secretagogue development and established the proof of concept that GHS-R1a selectivity was achievable. All subsequent work on selective GH secretagogues traces to the ipamorelin discovery.
Mechanism of Action
GHS-R1a agonism — GH release: Ipamorelin binds GHS-R1a receptors on pituitary somatotrophs and hypothalamic neurons with high affinity, activating phospholipase C (PLC) through Gq protein coupling. This initiates calcium mobilization from intracellular stores and PKC activation, driving GH vesicle exocytosis. The receptor specificity has been confirmed in blocking studies: GHS-R1a antagonist D-Lys3-GHRP-6 abolishes ipamorelin-induced GH release, confirming receptor-mediated action.
Dual hypothalamic and pituitary action: Like GHRP-6, ipamorelin requires an intact hypothalamic-pituitary connection for full in vivo GH-releasing potency. It acts at both the pituitary level (directly on somatotrophs) and the hypothalamic level (stimulating GHRH-releasing arcuate neurons and suppressing somatostatin tone), contributing to a GH release pattern that is pulsatile and physiologically appropriate in its timing and amplitude.
Selective HPA axis non-activation: Unlike GHRP-6 and GHRP-2, ipamorelin does not produce significant ACTH or cortisol elevation even at doses more than 200-fold above its GH ED50. The precise molecular basis for this selectivity — whether it reflects distinct receptor conformational states, differential G-protein coupling, or selective engagement of downstream signaling pathways — is an active area of pharmacological research. The selectivity appears to be a consequence of the unique Aib-containing structural scaffold rather than receptor subtype selectivity, as ipamorelin binds the same GHS-R1a receptor.
GHRH synergy: Ipamorelin acts synergistically with GHRH and GHRH analogs (CJC-1295, sermorelin, tesamorelin) when co-administered, reflecting complementary GHS-R1a (PLC/calcium) and GHRH-R (cAMP/PKA) intracellular signaling cascades converging on GH vesicle release. The combined GHRH+ipamorelin GH response substantially exceeds either compound alone — the same synergy principle established for all GHRP class compounds.
GI motility — GHS-R1a in the gastrointestinal tract: GHS-R1a receptors are expressed abundantly in the enteric nervous system and gastrointestinal smooth muscle, where ghrelin signaling drives gastric emptying and intestinal motility through cholinergic excitatory neuron activation. Ipamorelin activates these peripheral GHS-R1a receptors, stimulating gastric contractility and accelerating GI transit — an effect that is mechanistically distinct from its pituitary GH-releasing activity and has been the basis for ipamorelin’s investigation as a gastrointestinal promotility agent.
Bone effects: Published animal research has documented that ipamorelin increases bone mineral content when administered to growing rats, measured by DEXA scanning. This effect may reflect both direct GHS-R1a signaling in bone tissue and indirect effects mediated through GH-driven IGF-1 production. Animal studies have also demonstrated that ipamorelin can fully negate glucocorticoid-induced bone loss — a preclinical finding with potential relevance for osteoporosis research in corticosteroid-treated patient populations.
Published Research
Study 1 — Foundational Pharmacology: Ipamorelin as the First Selective Growth Hormone Secretagogue
Authors: Raun K, Hansen BS, Johansen NL, Thogersen H, Madsen K, Ankersen M, Andersen PH (Novo Nordisk) Year: 1998 Journal: European Journal of Endocrinology PMID: 9849822 Full text: https://pubmed.ncbi.nlm.nih.gov/9849822/
This foundational publication introduced ipamorelin to the scientific literature and established its defining pharmacological properties through systematic in vitro and in vivo characterization.
In vitro, ipamorelin released GH from primary rat pituitary cells with a potency and efficacy similar to GHRP-6 (EC50 equal to 1.3 plus or minus 0.4 nmol/L and Emax 85 plus or minus 5% versus 2.2 plus or minus 0.3 nmol/L and 100%) — establishing comparable in vitro GH secretagogue activity to the first-generation standard.
In pentobarbital-anaesthetized rats, ipamorelin released GH with potency and efficacy comparable to GHRP-6 (ED50 equal to 80 plus or minus 42 nmol/kg, Emax equal to 1545 plus or minus 250 ng GH/mL versus 115 plus or minus 36 nmol/kg and 1167 plus or minus 120 ng GH/mL in animals).
The specificity for GH release was studied systematically in swine. None of the GH secretagogues tested affected FSH, LH, PRL, or TSH. Administration of both GHRP-6 and GHRP-2 resulted in increased plasma levels of ACTH and cortisol — confirmed at statistically significant levels in the direct comparative data.
The study’s most significant finding: ipamorelin did not release ACTH or cortisol at levels significantly different from those observed following GHRH stimulation. This lack of HPA axis activation was evident even at doses more than 200-fold higher than the GH ED50 — directly demonstrating the extraordinary degree of selectivity relative to earlier GHRPs.
The authors concluded that ipamorelin is the first GHRP-receptor agonist with a selectivity for GH release similar to that displayed by GHRH, making it a very interesting candidate for future clinical development — a conclusion that positioned ipamorelin as the gold standard for selective GH secretagogue research.
Study 2 — Human Pharmacology: Ipamorelin Does Not Affect Cortisol, Prolactin, or Other Anterior Pituitary Hormones
Authors: Unpublished data referenced from the clinical development program; referenced via subsequent human studies Year: 1999 Journal: Referenced in subsequent literature as the study establishing human hormonal selectivity
Following the animal characterization in the 1998 Raun et al. publication, human pharmacology studies confirmed the selectivity findings in clinical subjects. Ipamorelin significantly and selectively increased plasma GH levels in healthy volunteers without any change in prolactin, FSH, LH, TSH, ACTH, or cortisol levels — directly translating the animal selectivity finding into human pharmacology.
The GH response to ipamorelin peaked at approximately 0.67 hours after administration and declined rapidly, consistent with a physiologically pulsatile GH secretion pattern.
These human selectivity data formed the foundation for ipamorelin’s clinical development trajectory, distinguishing it from earlier GHRPs that required management of HPA axis co-activation in any therapeutic application context.
Study 3 — Postoperative Ileus: Preclinical Evidence in Rodent Model
Authors: Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C Year: 2009 (animal model); 2012 (gastric dysmotility paper) Journal: Journal of Pharmacology and Experimental Therapeutics; Journal of Experimental Pharmacology PMID: 19289567 Full text: https://pubmed.ncbi.nlm.nih.gov/19289567/
This study systematically characterized ipamorelin’s gastrointestinal promotility effects in a rodent postoperative ileus model, providing the preclinical mechanistic foundation for subsequent human clinical trials.
Fasted male rats underwent laparotomy and intestinal manipulation to induce postoperative ileus. Ipamorelin administered by intravenous bolus or repetitive dosing regimen was compared to GHRP-6 and vehicle.
A single dose of ipamorelin at 1 mg/kg decreased the time to the first bowel movement compared to vehicle — demonstrating acute improvement in GI transit following surgical intestinal manipulation.
Repetitive dosing of ipamorelin at 0.1 or 1 mg/kg significantly increased cumulative fecal pellet output, food intake, and body weight gain over 48 hours post-surgery — demonstrating durable GI recovery effects with sustained dosing.
Mechanistic experiments in isolated gastric smooth muscle preparations showed that surgical manipulation markedly inhibited acetylcholine and electrical field stimulation-induced contractile responses, and that ipamorelin reversed these contractile deficits — implicating cholinergic excitatory neuron activation through GHS-R1a as the mechanism of the promotility effect.
The authors concluded that postsurgical intravenous infusions of ipamorelin may ameliorate the symptoms in patients with postoperative ileus, directly supporting clinical development in this indication.
Study 4 — Phase 2 Randomized Controlled Trial: Ipamorelin in Postoperative Ileus After Bowel Resection
Authors: Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group Year: 2014 Journal: International Journal of Colorectal Disease PMID: 25331030 Full text: https://pubmed.ncbi.nlm.nih.gov/25331030/
This prospective, randomized, controlled, proof-of-concept Phase 2 trial is the most advanced human clinical data for ipamorelin in any indication — a multi-center randomized controlled trial in patients undergoing bowel resection, evaluating ipamorelin as a treatment for postoperative ileus.
114 subjects were randomly allocated to receive intravenous ipamorelin at 0.03 mg/kg twice daily for up to 7 days beginning on postoperative day 1 (n equal to 56) or matching placebo (n equal to 58), following small and large bowel resection by open laparotomy or laparoscopic left colon resection.
Ipamorelin 0.03 mg/kg twice daily for up to 7 days was well tolerated, with no significant safety signals identified — confirming the favorable safety profile from preclinical and early clinical studies.
There were no statistically significant differences between ipamorelin and placebo in the key and secondary efficacy analyses at the dose and regimen studied — meaning the trial did not meet its primary endpoint at this specific dose level.
The authors characterized this as a proof-of-concept study explicitly designed to evaluate safety and tolerability, and to gather preliminary efficacy data for dose-finding purposes rather than as a definitive efficacy trial. The well-characterized safety and tolerability finding at this dose level supported the rationale for further dose-optimization studies in subsequent clinical development.
This trial is significant for the research catalog regardless of the efficacy outcome because it represents the most advanced human clinical development of any GHRP class compound other than GHRP-2 (pralmorelin), providing documented Phase 2 human safety data for ipamorelin and demonstrating that the compound is clinically evaluable.
Study 5 — Bone Mineral Content: Ipamorelin Increases BMC in Female Rats
Authors: Raun K et al. (Novo Nordisk, referenced in the original 1998 ipamorelin publication and subsequent reviews) Year: 1998 and subsequent animal studies Journal: Referenced from the original European Journal of Endocrinology publication
The original ipamorelin pharmacological characterization included assessment of bone mineral content (BMC) in adult female Sprague-Dawley rats. Treatment with ipamorelin significantly increased BMC as measured by DEXA — demonstrating an anabolic bone effect consistent with GH-driven IGF-1 elevation.
Additional preclinical studies demonstrated that ipamorelin can completely negate glucocorticoid-induced bone loss in animal models — a finding with potential research relevance for osteoporosis in corticosteroid-treated subjects, as glucocorticoid-induced osteoporosis represents one of the most common causes of secondary bone loss.
These bone findings, while preclinical, provided biological rationale for potential ipamorelin applications in sarcopenia and bone density research — clinical areas where GH axis modulation has well-established relevance but where existing therapies carry significant adverse effect profiles.
Ipamorelin in the GHRP Class: Defining Comparative Position
Ipamorelin’s research position within the GHRP class is defined by its selectivity. The practical implications for research protocol design are as follows.
When clean GH axis stimulation is required: Ipamorelin is the preferred GHRP because it does not co-elevate cortisol or ACTH — both of which have independent effects on metabolism, muscle, bone, and immune function that would confound interpretation of GH-mediated outcomes.
When appetite stimulation research is the endpoint: GHRP-6 is preferred because it produces the strongest orexigenic response in the class. Ipamorelin produces minimal appetite stimulation and is therefore not the appropriate tool for ghrelin receptor-mediated appetite biology studies.
When GH+GHRH synergy is the research design: Ipamorelin is the preferred GHRP for combination protocols with GHRH analogs (CJC-1295, sermorelin) because the synergistic GH amplification is achieved without introducing HPA axis activation that would accompany the same combination with GHRP-6 or GHRP-2.
When GI promotility is the research target: Ipamorelin has the most advanced clinical development data for gastrointestinal applications through its Phase 2 POI trial, and its peripheral GHS-R1a pharmacology is well characterized in this context.
When GH axis examination without tachyphylaxis is needed: Unlike hexarelin which shows pronounced receptor desensitization with repeated dosing, ipamorelin does not show significant tachyphylaxis — making it suitable for longer-duration GH axis research protocols.
An Honest Assessment of the Clinical Evidence Base
Ipamorelin’s most important clinical trial — the Beck et al. 2014 Phase 2 POI trial — did not demonstrate statistically significant efficacy at the dose level studied. This is accurately presented in the published literature and does not negate the compound’s research interest, as the trial was explicitly designed as a proof-of-concept safety and tolerability study rather than a definitive efficacy trial, and the safety data were favorable.
The preclinical pharmacology of ipamorelin is among the most thoroughly characterized of any GHRP compound, established by the Novo Nordisk development team and confirmed across multiple independent research groups. The human GH-releasing selectivity data has been confirmed. What remains limited is large-scale, long-term human clinical efficacy data for therapeutic GH axis applications — which is true of the entire GHRP class.
Current Research Status
Ipamorelin is not approved by the FDA for any therapeutic indication. It has been evaluated in at least one Phase 2 randomized controlled trial (postoperative ileus). The FDA has reviewed ipamorelin in the context of pharmaceutical compounding nominations. Research continues in GH axis optimization, GI promotility, body composition, bone biology, glucocorticoid-induced osteoporosis models, and as a combination partner with GHRH analogs. Ipamorelin is available for research through specialized peptide research sources.
Reconstitution Note
Ipamorelin is a synthetic pentapeptide. Bacteriostatic water is the standard reconstitution solvent. Ipamorelin dissolves readily in bacteriostatic water. Always confirm the recommended solvent against the specific lot datasheet before reconstitution.
In-Use Period and Storage
Before Reconstitution — Lyophilized Powder
Rogue Compounds stores all products refrigerated prior to shipping to maintain compound integrity from production through to delivery. Upon receipt researchers should store vials at 2 to 8 degrees Celsius immediately. Keep vials sealed, dry, and away from direct light until ready for use. Do not freeze. Repeated freeze-thaw cycling has been documented in peer-reviewed pharmaceutical formulation literature to accelerate structural degradation even in dry powder form, potentially compromising molecular integrity and experimental reproducibility.
Why We Refrigerate Instead of Freeze
Freezing and thawing introduces mechanical and osmotic stress at the molecular level. Published pharmaceutical research identifies freeze-thaw cycling as a significant risk factor for loss of structural integrity in peptides and protein-based compounds. To protect compound quality at every stage of handling and fulfillment, Rogue Compounds maintains refrigerated rather than frozen cold chain storage throughout the entire process.
After Reconstitution — Liquid Solution
Store reconstituted solutions refrigerated at 2 to 8 degrees Celsius immediately after preparation. Protect from light at all stages of storage and handling. Avoid repeated freeze-thaw cycles of reconstituted solutions regardless of the diluent used. Use within the timeframe recommended for the individual compound. Label each aliquot with the compound name, concentration, date of reconstitution, and diluent used. Discard any solution that shows visible particulate matter, discoloration, or signs of contamination.
Note: Storage and in-use recommendations on this page are provided as general laboratory guidance based on standard peptide handling practices documented in peer-reviewed pharmaceutical literature. Researchers should always refer to the individual compound’s published research literature and datasheet for any specific requirements. All products sold by Rogue Compounds are intended strictly for in-vitro laboratory research use only.
Available from Rogue Compounds
View the Ipamorelin product page: https://roguecompounds.com/product/ipamorelin/